Product Information
CARBIDOPA-LEVODOPA 25-250 TAB is a generic product labeled by Actavis Pharma, Inc., priced at $0.1104 per EA under NDC 00228254050. Its NADAC has been published 645 times since Nov 28, 2013.
FDA first approved this application on Sep 3, 1993. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 250 mg/1; mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00228254050
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
3/18/2026
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA074260FDA Approved
9/3/1993
TE Code
AB
On Market Since
9/1/1993
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVODOPA 25-250 TAB has been published 645 times since Nov 28, 2013, and over the history we have for it it has declined 39.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1104 per EA |
|---|---|
| All-time high | $0.2020 (Apr 15, 2015) |
| All-time low | $0.0731 (Apr 17, 2024) |
| 52-week high | $0.1334 |
| 52-week low | $0.1104 |
| Median price | $0.1717 |
| Average price | $0.1637 |
| Largest weekly change | +71.8% (Jun 19, 2024) |
| Weeks tracked | 645 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
N/A
6M
-3.9%
1Y
-17.2%
3Y
-19.7%
5Y
-34.4%
All
-39.4%
Last surveyed Apr 1, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVODOPA 25-250 TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVODOPA 25-250 TAB, manufactured by Actavis Pharma, Inc., is $0.1104 per EA (NDC 00228254050), effective Apr 1, 2026.
How has the price of CARBIDOPA-LEVODOPA 25-250 TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVODOPA 25-250 TAB has declined 39.4%. It has been tracked across 645 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVODOPA 25-250 TAB?
Since Nov 28, 2013, the NADAC for CARBIDOPA-LEVODOPA 25-250 TAB has ranged from a low of $0.0731 (Apr 17, 2024) to a high of $0.2020 (Apr 15, 2015), with a median of $0.1717 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVODOPA 25-250 TAB?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CARBIDOPA-LEVODOPA 25-250 TAB, is $0.1094 per EA — about 1% below CARBIDOPA-LEVODOPA 25-250 TAB.
Who manufactures CARBIDOPA-LEVODOPA 25-250 TAB?
CARBIDOPA-LEVODOPA 25-250 TAB (NDC 00228254050) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.